SG11201810951RA - Receptor selective retinoid and rexinoid compounds and immune modulators for cancer immunotherapy - Google Patents
Receptor selective retinoid and rexinoid compounds and immune modulators for cancer immunotherapyInfo
- Publication number
- SG11201810951RA SG11201810951RA SG11201810951RA SG11201810951RA SG11201810951RA SG 11201810951R A SG11201810951R A SG 11201810951RA SG 11201810951R A SG11201810951R A SG 11201810951RA SG 11201810951R A SG11201810951R A SG 11201810951RA SG 11201810951R A SG11201810951R A SG 11201810951RA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- california
- pct
- receptor
- retinoid
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 150000004492 retinoid derivatives Chemical class 0.000 title abstract 2
- 238000002619 cancer immunotherapy Methods 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 abstract 1
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 abstract 1
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102000034527 Retinoid X Receptors Human genes 0.000 abstract 1
- 108010038912 Retinoid X Receptors Proteins 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 abstract 1
- 238000009169 immunotherapy Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 102000003702 retinoic acid receptors Human genes 0.000 abstract 1
- 108090000064 retinoic acid receptors Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662348646P | 2016-06-10 | 2016-06-10 | |
US201662406779P | 2016-10-11 | 2016-10-11 | |
PCT/US2017/036870 WO2017214575A1 (en) | 2016-06-10 | 2017-06-09 | Receptor selective retinoid and rexinoid compounds and immune modulators for cancer immunotherapy |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201810951RA true SG11201810951RA (en) | 2019-01-30 |
Family
ID=60572126
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201810951RA SG11201810951RA (en) | 2016-06-10 | 2017-06-09 | Receptor selective retinoid and rexinoid compounds and immune modulators for cancer immunotherapy |
Country Status (12)
Country | Link |
---|---|
US (10) | US9907768B2 (de) |
EP (1) | EP3468600A4 (de) |
JP (1) | JP2019517557A (de) |
KR (1) | KR20190017950A (de) |
CN (2) | CN115671292A (de) |
AU (2) | AU2017278220C1 (de) |
CA (1) | CA3026563C (de) |
IL (1) | IL263629B2 (de) |
MX (1) | MX2018015352A (de) |
SG (1) | SG11201810951RA (de) |
WO (1) | WO2017214575A1 (de) |
ZA (1) | ZA201807809B (de) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT3273992T (pt) * | 2015-03-23 | 2020-08-21 | Jounce Therapeutics Inc | Anticorpos para icos |
WO2017091762A1 (en) | 2015-11-25 | 2017-06-01 | Io Therapeutics, Inc. | Use of cyp26-resistant rar alpha selective agonists in the treatment of cancer |
EP3468600A4 (de) | 2016-06-10 | 2019-11-13 | IO Therapeutics, Inc. | Rezeptorselektive retinoid- und rexinoidverbindungen und immunmodulatoren zur krebsimmuntherapie |
WO2019014468A1 (en) | 2017-07-13 | 2019-01-17 | Io Therapeutics, Inc. | RECEPTOR SUBTYPE AND RETINOID COMPOUNDS AND SELECTIVE REXINOIDS OF A FUNCTION IN COMBINATION WITH IMMUNE MODULATORS FOR ANTICANCER IMMUNOTHERAPY |
WO2019046591A1 (en) | 2017-08-31 | 2019-03-07 | Io Therapeutics, Inc. | SELECTIVE RAR AGONISTS IN ASSOCIATION WITH IMMUNE MODULATORS IN ANTICANCER IMMUNOTHERAPY |
WO2019099949A1 (en) * | 2017-11-17 | 2019-05-23 | The Regents Of The University Of California | Manipulation of the retinoic acid signaling pathway |
US20210008047A1 (en) * | 2018-02-13 | 2021-01-14 | Vib Vzw | Targeting minimal residual disease in cancer with rxr antagonists |
GB201805963D0 (en) * | 2018-04-11 | 2018-05-23 | Avacta Life Sciences Ltd | PD-L1 Binding Affirmers and Uses Related Thereto |
CA3101640A1 (en) * | 2018-06-04 | 2019-12-12 | Trustees Of Tufts College | Tumor microenvironment-activated drug-binder conjugates, and uses related thereto |
CN109136373A (zh) * | 2018-08-27 | 2019-01-04 | 中山大学 | 一种用于早期诊断肺癌转移的lncRNA检测试剂盒及其应用 |
WO2020128478A1 (en) * | 2018-12-19 | 2020-06-25 | King's College London | Immunotherapeutic methods and compositions |
EP3911309A4 (de) * | 2019-01-17 | 2023-01-25 | Board Of Trustees Of Michigan State University | Zusammensetzungen und verfahren zur immunmodulierung und behandlung von krebs |
US20200352958A1 (en) * | 2019-05-10 | 2020-11-12 | The Trustees Of The University Of Pennsylvania | Methods And Compositions For Targeting Retinoic Acid For Solid Tumor Immunotherapy |
KR20220066142A (ko) * | 2019-10-16 | 2022-05-23 | 주식회사 엘지화학 | 신생아 에프씨 수용체 결합 아피머 |
CA3239689A1 (en) * | 2021-11-23 | 2023-06-01 | Io Therapeutics, Inc. | Methods of using rar.gamma. agonists for cancer treatment |
US11976021B2 (en) | 2022-06-27 | 2024-05-07 | Io Therapeutics, Inc. | Synthesis of tetrahydronaphthalenols and uses thereof |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4326055A (en) | 1977-12-22 | 1982-04-20 | Hoffmann-La Roche Inc. | Stilbene derivatives |
US5234926A (en) | 1987-03-20 | 1993-08-10 | Allergan, Inc. | Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity |
US5324840A (en) | 1992-06-11 | 1994-06-28 | Allergan, Inc. | Method of treatment with compounds having retinoid-like activity and reduced skin toxicity and lacking teratogenic effects |
DK0638071T3 (da) | 1992-12-28 | 1997-10-27 | Eisai Co Ltd | Heterocykliske carboxylsyrederivater, der bindes til retenoidreceptorer (RAR) |
CA2138000A1 (en) | 1994-01-03 | 1995-07-04 | John E. Starrett, Jr. | Retinoid-like compounds |
US5824685A (en) | 1995-02-01 | 1998-10-20 | The Johns Hopkins University School Of Medicine | Method of preventing proliferation of retinal pigment epithelium by retinoic acid receptor agonists |
US5776699A (en) | 1995-09-01 | 1998-07-07 | Allergan, Inc. | Method of identifying negative hormone and/or antagonist activities |
US5958954A (en) | 1995-09-01 | 1999-09-28 | Allergan Sales, Inc. | Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities |
FR2739557B1 (fr) * | 1995-10-09 | 1997-11-14 | Cird Galderma | Utilisation d'un ligand agoniste specifique rar-gamma |
US20030092758A1 (en) * | 1995-10-09 | 2003-05-15 | Laszlo Fesus | Use of a RAR-gamma-specific agonist ligand for increasing the rate of apoptosis |
US5877207A (en) | 1996-03-11 | 1999-03-02 | Allergan Sales, Inc. | Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities |
US5723666A (en) | 1996-06-21 | 1998-03-03 | Allergan | Oxime substituted tetrahydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity |
JP2001500486A (ja) * | 1996-08-28 | 2001-01-16 | アンスティテュ ナショナル デゥ ラ サンテ エ デゥ ラ ルシェルシュ メディカル | Rarアンタゴニストとrxrアゴニストとの治療学的組合せおよびその使用 |
US5739338A (en) | 1996-11-05 | 1998-04-14 | Allergan | N-aryl substituted tetrahydroquinolines having retinoid agonist, retinoid antagonist or retinoid inverse agonist type biological activity |
US6037488A (en) | 1997-04-19 | 2000-03-14 | Allergan Sales, Inc. | Trisubstituted phenyl derivatives having retinoid agonist, antagonist or inverse agonist type biological activity |
US5919970A (en) | 1997-04-24 | 1999-07-06 | Allergan Sales, Inc. | Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity |
US6326397B1 (en) * | 1998-11-10 | 2001-12-04 | Hoffman-La Roche Inc. | Retinoid antagonists and use thereof |
DE60016404T2 (de) | 1999-06-11 | 2005-10-27 | Allergan, Inc., Irvine | Organosiliciumvebindungen mit der fähigkeit zur modulation von im zellkern lokalisierten hormonrezeptoren |
AU6228000A (en) | 1999-07-23 | 2001-02-13 | Allergan Sales, Inc. | The use of retinoid receptor antagonists in the treatment of prostate carcinoma |
PL208665B1 (pl) | 2000-10-02 | 2011-05-31 | Hoffmann La Roche | Związki retinoidowe, ich zastosowanie, środek farmaceutyczny i sposób wytwarzania związków retinoidowych |
BRPI0410454A (pt) * | 2003-05-19 | 2006-06-13 | Irm Llc | composições e compostos imunossupressores |
BRPI0616454A2 (pt) * | 2005-09-30 | 2011-06-21 | Vitae Pharmaceuticals Inc | métodos de tratamento de cáncer |
TR201819157T4 (tr) | 2006-05-16 | 2019-01-21 | Io Therapeutics Llc | Kemoterapi Ve Veya Radyasyon Terapisinin Yan Etkilerinin Tedavisinde Kullanıma Yönelik Rar Antagonisti Veya Ters Agonisti |
WO2008137488A1 (en) * | 2007-05-01 | 2008-11-13 | Purdue Research Foundation | Methods for controlling inflammatory and immunological diseases |
AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
WO2012112623A2 (en) * | 2011-02-14 | 2012-08-23 | Sloan-Kettering Institute For Cancer Research | Rxrg modulators for the treatment of cancer |
WO2012125724A1 (en) * | 2011-03-14 | 2012-09-20 | Beth Israel Deaconess Medical Center | Methods and compositions for the treatment of proliferative disorders |
CA2899577C (en) * | 2013-04-03 | 2023-10-17 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
EP3770176A1 (de) | 2013-05-02 | 2021-01-27 | AnaptysBio, Inc. | Antikörper gegen programmierten tod-1 (pd-1) |
US20150164907A1 (en) * | 2013-11-17 | 2015-06-18 | Angion Biomedica Corp. | Compositions and methods for treating disease |
SI3083616T1 (sl) * | 2013-12-20 | 2021-12-31 | Astex Therapeutics Limited | Biciklične heterociklične spojine in njihova uporaba pri zdravljenju |
PE20161344A1 (es) * | 2014-01-02 | 2016-12-23 | Memorial Sloan Kettering Cancer Center | Determinantes de respuesta del cancer a la inmunoterapia |
WO2015131176A1 (en) * | 2014-02-28 | 2015-09-03 | Podack Eckhard R | Compositions, methods, and kits for treatment of cancer |
EP3936145A1 (de) * | 2014-07-31 | 2022-01-12 | The University Of Western Australia | Verfahren zur identifizierung von immuntherapie-arzneimittel-kombinationen unter verwendung eines netzwerkansatzes |
SG11201701710SA (en) * | 2014-09-08 | 2017-04-27 | Celgene Corp | Methods for treating a disease or disorder using oral formulations of cytidine analogs in combination with an anti-pd1 or anti-pdl1 monoclonal antibody |
JP2018512396A (ja) * | 2015-03-09 | 2018-05-17 | キングス・カレッジ・ロンドン | Th1応答を増強するためのrarアルファアゴニストを用いた併用療法 |
WO2017201200A1 (en) * | 2016-05-19 | 2017-11-23 | Orphagen Pharmaceuticals, Inc. | Therapeutic compositions containing rar-alpha antagonists |
EP3468600A4 (de) | 2016-06-10 | 2019-11-13 | IO Therapeutics, Inc. | Rezeptorselektive retinoid- und rexinoidverbindungen und immunmodulatoren zur krebsimmuntherapie |
WO2019014468A1 (en) * | 2017-07-13 | 2019-01-17 | Io Therapeutics, Inc. | RECEPTOR SUBTYPE AND RETINOID COMPOUNDS AND SELECTIVE REXINOIDS OF A FUNCTION IN COMBINATION WITH IMMUNE MODULATORS FOR ANTICANCER IMMUNOTHERAPY |
-
2017
- 2017-06-09 EP EP17811125.8A patent/EP3468600A4/de active Pending
- 2017-06-09 KR KR1020197000997A patent/KR20190017950A/ko not_active IP Right Cessation
- 2017-06-09 SG SG11201810951RA patent/SG11201810951RA/en unknown
- 2017-06-09 JP JP2018564359A patent/JP2019517557A/ja active Pending
- 2017-06-09 CN CN202211285002.0A patent/CN115671292A/zh active Pending
- 2017-06-09 CA CA3026563A patent/CA3026563C/en active Active
- 2017-06-09 WO PCT/US2017/036870 patent/WO2017214575A1/en unknown
- 2017-06-09 MX MX2018015352A patent/MX2018015352A/es unknown
- 2017-06-09 AU AU2017278220A patent/AU2017278220C1/en active Active
- 2017-06-09 CN CN201780035846.0A patent/CN109310763B/zh active Active
- 2017-06-12 US US15/620,411 patent/US9907768B2/en active Active
-
2018
- 2018-01-11 US US15/868,450 patent/US10004708B2/en active Active
- 2018-01-11 US US15/868,469 patent/US10123982B2/en active Active
- 2018-01-11 US US15/868,459 patent/US10004709B2/en active Active
- 2018-01-11 US US15/868,391 patent/US20180133179A1/en not_active Abandoned
- 2018-01-11 US US15/868,432 patent/US20180133180A1/en not_active Abandoned
- 2018-07-31 US US16/050,441 patent/US20180338941A1/en not_active Abandoned
- 2018-11-20 ZA ZA2018/07809A patent/ZA201807809B/en unknown
- 2018-12-05 US US16/211,045 patent/US20190105292A1/en not_active Abandoned
- 2018-12-10 IL IL263629A patent/IL263629B2/en unknown
-
2021
- 2021-03-26 US US17/213,579 patent/US20210275478A1/en not_active Abandoned
-
2022
- 2022-03-03 US US17/685,626 patent/US11648223B2/en active Active
- 2022-10-19 AU AU2022256117A patent/AU2022256117A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201810951RA (en) | Receptor selective retinoid and rexinoid compounds and immune modulators for cancer immunotherapy | |
SG11202000263QA (en) | Immunomodulatory retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy | |
SG11201908391XA (en) | Methods for modulating an immune response | |
SG11201807401RA (en) | Therapeutic membrane vesicles | |
SG11201811564QA (en) | Methods of treating ovarian cancer | |
SG11201807176XA (en) | TGFß1-BINDING IMMUNOGLOBULINS AND USE THEREOF | |
SG11201901126UA (en) | Combination therapy for cancer | |
SG11201805828YA (en) | Method of treating c3 glomerulopathy | |
SG11201811549UA (en) | Boronic acid derivatives and therapeutic uses thereof | |
SG11201903882VA (en) | Il-2 variants for the treatment of autoimmune diseases | |
SG11201900344YA (en) | Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor | |
SG11201808990QA (en) | Compositions for topical application of compounds | |
SG11201806322QA (en) | Maytansinoid derivatives, conjugates thereof, and methods of use | |
SG11201807255YA (en) | Treatment of autoimmune diseases with combinations of rxr agonists and thyroid hormones | |
SG11201807250PA (en) | Treatment of muscular disorders with combinations of rxr agonists and thyroid hormones | |
SG11201808125RA (en) | Methods for solid tumor treatment | |
SG11201807421TA (en) | The use of glucocorticoid receptor modulators to potentiate checkpoint inhibitors | |
SG11201811225RA (en) | Ar+ breast cancer treatment methods | |
SG11201806496SA (en) | Antigen binding proteins that bind pd-l1 | |
SG11201807784SA (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
SG11201806251WA (en) | Methods for treating er+, her2-, hrg+ breast cancer using combination therapies comprising an anti-erbb3 antibody | |
SG11201810525XA (en) | Anti-gitr antibodies and uses thereof | |
SG11201906853QA (en) | Anti-rsv monoclonal antibody formulation | |
SG11201807597UA (en) | Methods of treating depression using orexin-2 receptor antagonists | |
SG11201909501TA (en) | Personalized 3d neural culture system for generating human oligodendrocytes and studying myelination in vitro |